ASA. Yu. Startseva

A. Yu. Startseva

*This is an algorithmically generated author record based on publicly available information.

A. Yu. Startseva has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mesenchymal stem cells in liver transplantation: аssessment of long-term results

    by S. V. Korotkov, E. A. Nazarova, E. G. Yurkina, В. В. Смольникова, V. Yu. Grinevich, E. A. Yanushevskaya, A. Yu. Startseva, A. E. Shcherba, S. I. Krivenko, O. O. Rummo, et al.

    Introduction. Transplantation is an effective method of treating patients with end stage liver diseases. Long-term results are determined by two main factors: the development of immunological complications and calcineurin inhibitor nephrotoxity. Application of mesenchymal stem cells (MSCs), which modulate the immune response, is a promising effective method to optimize the treatment results in patients after liver transplantation.The objective of the study was to evaluate the long-term results of mesenchymal stem cells application in liver transplantation.Material and methods. A retrospective study was performed, which included 186 patients after liver transplantation (2015–2023). The MSC group (n=93) received MSCs according to four protocols: local, systemic, combined administration, therapy for acute kidney injury; the control group (n=93) received the standard treatment. The median follow-up was 3 (2;5) years, the follow-up period being from 1-8 years. The patient survival, graft and renal function, depth of immunosuppressive therapy, anti-HLA antibody levels, and lymphocyte immunophenotype were assessed.Results. In the MSC group the incidence of immunological dysfunction of the liver allograft was decreased (22% versus 40%, pConclusion. Using MSCs in liver transplantation improves long-term outcomes by reducing the incidence of immunological complications, preserves the renal function, and reduces the need for high-dose immunosuppression.

  • Open Access

    Functional characteristics of lymphocytes and plasma cytokine profile of allogeneic hematopoietic stem cell recipients as risk factors for the development of acute graft-versus-host disease

    by E. A. Prymakova, S. I. Krivenko, A. A. Symanovich, E. G. Yurkina, E. A. Nazarova, E. A. Yanushevskaya, I. N. Dedyulya, I. A. Romanova, H. Y. Startsava, N. F. Milanovich, et al.

    It has been shown that in order to identify patients with high risk for developing immunological complications after allogeneic hematopoietic stem cell transplantation (alloHSCT), it is advisable to measure quantitatively the proliferative activity of lymphocytes in alloHSCT recipients on the day of transplantation. A high donor and recipient lymphocyte stimulation index (>11.55) is an unfavorable factor in terms of development of a graft-versus-host disease (GVHD) in the early posttransplant period. In the course of the work, it was found that the study of the cytokine profile of blood plasma of alloHSC recipients in the early posttransplant period can be used as an additional method for diagnosing GVHD. The levels of IL-8 and IL-21 in the blood plasma of alloHSC recipients can act as potential biomarkers of acute GVHD.